[1]中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
[2]郑晓敏, 杨芳远, 刘翠平, 等. 触珠蛋白对早期糖尿病肾病患者肾功能损害的预测作用[J]. 首都医科大学学报, 2019, 40(1): 53-58.
[3]Bonakdaran S, Hami M, Hatefi A. The effects of calcitriol on albuminuria in patients with type-2 diabetes mellitus[J]. Saudi J Kidney Dis Transpl, 2012, 23(6): 1215-1220.
[4]Obaid A A, Mujalli A, Farrash W F, et al. Relationship of vitamin-D deficiency with kidney disease in patients with type-2 diabetes mellitus (T2DM) in the Makkah region: a cross-sectional study[J]. Diabetes Metab Syndr Obes, 2024, 17: 11-17.
[5]Huang Y, Yu H Y, Lu J X, et al. Oral supplementation with cholecalciferol 800 IU ameliorates albuminuria in Chinese type 2 diabetic patients with nephropathy[J]. PLoS One, 2012, 7(11): e50510.
[6]Xu F, Lu H Y, Lai T W, et al. Association between vitamin D status and mortality among adults with diabetic kidney disease[J]. J Diabetes Res, 2022, 2022: 9632355.
[7]Gupta S, Goyal P, Feinn R S, et al. Role of vitamin D and its analogues in diabetic nephropathy: a meta-analysis[J]. Am J Med Sci, 2019, 357(3): 223-229.
[8]Charoenngam N, Holick M F. Immunologic effects of vitamin D on human health and disease[J]. Nutrients, 2020, 12(7): 2097.
[9]Contreras B V, García F B, García F C, et al. Mechanisms involved in the relationship between vitamin D and insulin resistance: impact on clinical practice[J]. Nutrients, 2021, 13(10): 3491.
[10]Derakhshanian H, Djazayery A, Javanbakht M H, et al. The effect of vitamin D on cellular pathways of diabetic nephropathy[J]. Rep Biochem Mol Biol, 2019, 7(2): 217-222.
[11]de Oliveira E Silva Ullmann T, Ramalho B J, Laurindo L F, et al. Effects of vitamin D supplementation in diabetic kidney disease: an systematic review[J]. J Ren Nutr, 2023, 33(5): 618-628.
[12]de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial[J]. Lancet, 2010, 376(9752): 1543-1551.
[13]Mustafar R, Mohd R, Ahmad Miswan N, et al. The effect of calcium with or without calcitriol supplementation on renal function in patients with hypovitaminosis d and chronic kidney disease[J]. Nephrourol Mon, 2014, 6(1): e13381.
[14]Sprague S M, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism[J]. Kidney Int, 2003, 63(4): 1483-1490.
[15]Bolland M J, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the women's health initiative limited access dataset and meta-analysis[J]. BMJ, 2011, 342: d2040.
[16]Dyer C A. Safety and tolerability of paricalcitol in patients with chronic kidney disease[J]. Expert Opin Drug Saf, 2013, 12(5): 717-728.
[17]Franchi M, Gunnarsson J, Gonzales P E, et al. Paricalcitol and extended-release calcifediol for treatment of secondary hyperparathyroidism in non-dialysis chronic kidney disease: results from a network meta-analysis[J]. J Clin Endocrinol Metab, 2023, 108(11): e1424-e1432.
[18]Ri K R, Fukasawa T, Masuda S, et al. Frequency and determinants of serum calcium monitoring during eldecalcitol therapy in patients with osteoporosis[J]. J Bone Miner Metab, 2023, 41(6): 890-900.
[19]Aihara S, Yamada S S E, Oka H, et al. Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility[J]. Ren Fail, 2019, 41(1): 88-97.
[20]Kondo S, Kakihata H, Nishida Y S E, et al. The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese male patients with osteoporosis[J]. J Bone Miner Metab, 2019, 37(2): 292-300.
[21]Cui L J, Xia W B, Yu C, et al. Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis[J]. Arch Osteoporos, 2022, 17(1): 74.
[22]Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int, 2022, 102(5S): S1-S127.
[23]Souza C S, Deluque A L, Oliveira B M, et al. Vitamin D deficiency contributes to the diabetic kidney disease progression via increase ZEB1/ZEB2 expressions[J]. Nutr Diabetes, 2023, 13(1): 9.
[24]Zhang X Y, Zhang L, Wen Y Z, et al. Vitamin D ameliorates podocyte injury by enhancing autophagy activity in diabetic kidney disease[J]. Kidney Blood Press Res, 2023, 48(1): 314-325.
[25]Qu Y, Wu Y C, Jiang H. Research progress in the pharmacological actions of the multiple effects and selectivity of the vitamin D analogue paricalcitol: a narrative review[J]. Ann Palliat Med, 2021, 10: 11177-11190.
[26]Martínez A L, Panizo S, Alonso M C, et al. Effects of calcitriol and paricalcitol on renal fibrosis in CKD[J]. Nephrol Dial Transplant, 2021, 36(5): 793-803.
[27]Ajabshir S, Asif A, Nayer A. The effects of vitamin D on the renin-angiotensin system[J]. J Nephropathol, 2014, 3(2): 41-43.
[28]Chevalley T, Brandi M L, Cashman K D, et al. Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European society of clinical and economical aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO) working group[J]. Aging Clin Exp Res, 2022, 34(11): 2603-2623.
[29]中华医学会骨质疏松和骨矿盐疾病分会. 维生素D及其类似物临床应用共识[J]. 中华骨质疏松和骨矿盐疾病杂志, 2018, 11(1): 1-19.
[30]Vieth R. Vitamin D supplementation: cholecalciferol, calcifediol, and calcitriol[J]. Eur J Clin Nutr, 2020, 74(11): 1493-1497.
[31]Tripkovic L, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis[J]. Am J Clin Nutr, 2012, 95(6): 1357-1364.
[32]Holick M F, Biancuzzo R M, Chen T C, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D[J]. J Clin Endocrinol Metab, 2008, 93(3): 677-681.
|